CBS 2019
CBSMD教育中心
English

左主干支架

科研文章

荐读文献

Contemporary Approach to Coronary Bifurcation Lesion Treatment Surgical ineligibility and mortality among patients with unprotected left main or multivessel coronary artery disease undergoing percutaneous coronary intervention Left Main Stenting: What We Have Learnt So Far? Percutaneous Coronary Intervention Using Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Unprotected Left Main Coronary Artery Stenosis: A Meta-Analysis of Randomized Trials Intravascular Imaging and 12-Month Mortality After Unprotected Left Main Stem PCI: An Analysis From the British Cardiovascular Intervention Society Database Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease The Current State of Left Main Percutaneous Coronary Intervention Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial Impact of different final optimization techniques on long-term clinical outcomes of left main cross-over stenting 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy
|<< 1 2 3 4 5 6 7 ...>>|

Editorial2018 Jul;28(5):365-366.

JOURNAL：Trends Cardiovasc Med. Article Link

Novel developments in revascularization for left main coronary artery disease

Carreras ET, Bhatt DL. Keywords: DK CRUSH; LM bifurcation lesions; evidence-based

Article Link

Please click on the "Article Link" on the right to get access to this article.


Quotation

"When PCI is used to treat LM bifurcation lesions,

DK-CRUSH is the most reasonable evidence-based approach."


>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top